Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Colorcon
Chinese Patent Office
Medtronic
Baxter
Covington

Generated: May 27, 2019

DrugPatentWatch Database Preview

GEMTUZUMAB OZOGAMICIN - Generic Drug Details

« Back to Dashboard

What are the generic sources for gemtuzumab ozogamicin and what is the scope of gemtuzumab ozogamicin freedom to operate?

Gemtuzumab ozogamicin is the generic ingredient in one branded drug marketed by Wyeth Pharms Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for GEMTUZUMAB OZOGAMICIN

US Patents and Regulatory Information for GEMTUZUMAB OZOGAMICIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for GEMTUZUMAB OZOGAMICIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Accenture
Colorcon
Mallinckrodt
Express Scripts
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.